Reference is made to Navamedic’s communicated target of 20% annual growth for 2021. As the company’s preliminary financial results for Q4, and hence the full year 2021, represent a noticeable improvement compared to the communicated target for 2021, the company has decided to provide a trading update based on an updated revenue growth expectation for the full-year 2021 of around 30%.

“Our portfolio of specialty pharma and consumer health products continues to grow with particularly strong performance for the obesity product Mysimba. The growth in the fourth quarter and December in particular has been stronger than expected. We are pleased to see this development, and to provide an updated revenue growth expectation for the full year 2021 compared to 2020 of around 30%,” says Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic ASA.

Navamedic wants to reiterate that that the books for Q4 2021 are not closed, that the revenue growth in 2021 thus at this stage is an estimate and that the final numbers will be communicated on Navamedic’s presentation of the Q4 numbers on February 17, 2022.

Going into 2022, Navamedic maintains its annual growth target of 20% and its mid-term ambition of building a NOK 500 million company through organic growth with strong gross margins and underlying profitability.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. The information was submitted for publication, through Newsweb by Lars Hjarrand at 13:34 hrs CET on 23 December 2021.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47917 62 842
E-mail: lars.hjarrand@navamedic.com

About

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visitwww.navamedic.com